Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106108 | 0.85 | ALDH1A1 (0.54) | CCR1NR3C1ALDH1A1LMNATDP1 | |
| SCHEMBL305477 | 0.81 | FGFR1 (0.47) | ALDH1A1LMNATDP1CYP3A4CYP2C9 | |
| SCHEMBL443252 | 0.77 | CCR1 (0.46) | CCR1NR3C1CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL441916 | 0.77 | CCR1 (0.46) | CCR1NR3C1CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL4572945 | 0.77 | MKNK1 (0.47) | CCR1NR3C1CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL1255335 | 0.75 | CCR1 (0.58) | CCR1NR3C1 | |
| SCHEMBL19533517 | 0.73 | PIN1 (0.42) | ALDH1A1LMNATDP1CYP3A4CYP2C9 | |
| SCHEMBL4555832 | 0.73 | TDP1 (0.50) | ALDH1A1LMNATDP1CYP3A4CYP2C9 | |
| SCHEMBL29687237 | 0.73 | TDP1 (0.50) | ALDH1A1LMNATDP1CYP3A4CYP2C9 | |
| SCHEMBL15797015 | 0.71 | CYP1A2 (0.54) | ALDH1A1LMNATDP1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008055710-A1 | INDOLE AND INDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055709-A1 | INDAZOLE AND INDOLE DERIVATIVES AS ANTI -INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921068-A1 | Indazole and indole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921067-A1 | Indole and indazole derivatives as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008052808-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1917963-A1 | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGIS, PTGS1, PTGES | CCR1 347/4885NR3C1 865/4885ALDH1A1 238/4885 |
| US-20080188666-A1 | LINEAR PHENYL-SUBSTITUTED INDAZOLES AND INDOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | IDO1, IL1B, IDO2 | CCR1 755/4885NR3C1 1243/4885ALDH1A1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.